Cutting-Edge Research in Exosomes and Extracellular Vesicles

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cell Biology and Pathology".

Deadline for manuscript submissions: 31 May 2025 | Viewed by 1138

Special Issue Editor


E-Mail Website
Guest Editor
1.Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, VIC 3002, Australia
2.Ophthalmology, Department of Surgery, University of Melbourne, Melbourne, VIC 3000, Australia
Interests: mitochondria; neurodegeneration research; retinal gene therapy; exosomes; extracellular vesicles

Special Issue Information

Dear Colleagues,

The field of exosomes and extracellular vesicles (EVs) has witnessed significant breakthroughs, highlighting their potential as drug delivery system and therapeutic applications. This Special Issue aims to consolidate cutting-edge research and comprehensive reviews that explore the latest advancements in exosome and EV biology, with a particular emphasis on their role as targeted drug delivery vehicles. We invite contributions that investigate the mechanisms of exosome biogenesis, innovative methodologies for EV isolation and characterization, and the molecular profiling of exosomal cargo, including proteins, lipids, RNAs, and metabolites.

This Special Issue will focus on the clinical applications of exosomes including their use in targeted drug delivery systems, cancer therapy, and treatment of neurodegenerative diseases, and with a special interest in retinal diseases. Studies exploring the engineering of exosomes for enhanced delivery efficiency, biocompatibility, and specific targeting are particularly encouraged. Additionally, research on the use of exosomes as biomarkers for disease diagnostics and their potential in immune modulation and regenerative medicine will be featured.

By showcasing these pioneering studies, this Special Issue aims to provide a comprehensive overview of the current landscape and future directions in exosome and EV research. We seek to foster interdisciplinary collaborations and inspire novel approaches that will drive the field forward, ultimately translating these biological insights into clinical and therapeutic innovations.

Dr. Sushma Anand
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • drug delivery
  • targeted therapy
  • EV engineering
  • cargo loading
  • molecular profiling
  • retinal degeneration
  • neurodegenerative disease
  • therapeutic application

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

20 pages, 7302 KiB  
Article
Development of LncRNA Biomarkers in Extracellular Vesicle of Amniotic Fluid Associated with Antenatal Hydronephrosis
by Ying Fu, Qiaoshu Liu, Ruojin Yao, Yimei Fu, Lei Dai, Wenyan Jian, Weishe Zhang and Jingzhi Li
Biomedicines 2025, 13(3), 668; https://doi.org/10.3390/biomedicines13030668 - 8 Mar 2025
Viewed by 685
Abstract
Background: Antenatal hydronephrosis (ANH) is the most common congenital renal and urinary tract anomaly, and parenchymal damage and renal fibrosis due to pathological hydronephrosis are the main causes of end-stage renal disease in children and chronic kidney disease in adults. At present, [...] Read more.
Background: Antenatal hydronephrosis (ANH) is the most common congenital renal and urinary tract anomaly, and parenchymal damage and renal fibrosis due to pathological hydronephrosis are the main causes of end-stage renal disease in children and chronic kidney disease in adults. At present, there is no validated biomarker for ANH, and diagnostic criteria other than prenatal ultrasonography (US) assessment are lacking. Therefore, we assessed to determine if biomarkers extracted from amniotic fluid small extracellular vesicles (sEVs) might be used as ANH diagnosis. Methods: With congenital ureteropelvic junction obstruction (UPJO) as the ultimate diagnosis, 10 pregnant women with Grade III-IV ANH and 10 normal pregnant women were recruited. The sEVs were extracted from amniotic fluid supernatant of all samples. Transcriptomic sequencing of sEVs in the discovery cohort identified the differential expression profiles for ANH. The known differentially expressed lncRNAs (DE-lncRNAs) were assessed by qRT–PCR in the validation cohort. Results: We explored the global RNA expression in sEVs from amniotic fluid. The differential expression profiles of both mRNAs and lncRNAs were related to fetal kidney development. Six known DE-lncRNAs were identified for ANH, and three of those with high expression were verified in more ANH samples. In particular, the upregulated LINC02863 and its target genes were associated with renal development and morphogenesis. The four predicted novel lncRNAs in high expression were also related to mesenchymal morphogenesis and the STAT3 signaling pathway and may play roles in ANH. Conclusions: We identified differentially expressed RNAs of all species in the sEVs from amniotic fluid, and the validated known DE-lncRNAs might serve as promising diagnostic biomarkers for ANH. Full article
(This article belongs to the Special Issue Cutting-Edge Research in Exosomes and Extracellular Vesicles)
Show Figures

Figure 1

Back to TopTop